Uncategorized

Replimune’s advanced melanoma drug rebuffed by FDA for second time

Published

on

The FDA in a complete response letter to Replimune maintained its original objection to the single-arm trial the biotech used to support the application for RP1.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version